Physician profile
Anna B Edhegard
NPI 1164657391
$12,914.16
in general payments reported to CMS, 2019-2025
40 companies · $2,574 in 2025
The $2,574 reported for 2025 was more than what 82% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,419 · 2020: $807 · 2021: $1,029 · 2022: $1,887 · 2023: $2,619 · 2024: $2,580 · 2025: $2,574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,410 · Education: $363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,409.61 |
| Education | $362.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,851.37 | 2019-2025 | Skyrizi, Rinvoq |
| Lilly USA, LLC | $1,240.84 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $1,118.60 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $1,089.63 | 2019-2025 | Ilumya, Odomzo, Blu-U |
| Janssen Biotech, INC. | $1,076.33 | 2019-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $780.66 | 2019-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $697.83 | 2019-2025 | Nemluvio, Aklief |
| Genzyme Corporation | $673.66 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $668.74 | 2023-2025 | Sotyktu |
| Leo Pharma INC. | $586.84 | 2019-2025 | Adbry |
| Ucb, INC. | $581.32 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Scientific Affairs, LLC | $433.06 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $388.69 | 2019-2025 | |
| Amgen INC. | $337.32 | 2019-2023 | Otezla, Enbrel |
| Dermavant Sciences, INC. | $202.34 | 2023-2024 | Vtama |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Edhegard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.